Due to the significant adverse effects of dabrafenib–trametinib and its low efficacy, the dabrafenib–trametinib combination is usually used as a second line after the chemoimmunotherapy combination with pembrolizumab in metastatic NSCLC with BRAF mutations, unlike other tyrosine kinase inhibitors, which are used in the first-line setting for specific molecular alterations. This evidence concerns the gene BRAF and non-small cell lung carcinoma.